Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.